In the battle against Alzheimer’s disease and dementia, hope is on the horizon. With groundbreaking treatments like Leqembi (lecanemab) hitting the market and a robust pipeline of over 140 agents in development, health care providers are armed with potent tools. Alvaro Pascual-Leone, M.D., Ph.D., and Dr. John Showalter, M.D., experts in cognitive care, will guide you through this changing landscape. Learn about the power of early detection, the synergy of drug and lifestyle interventions, and the role of modern cognitive assessment tools in streamlining care.
Encouraging developments in the fight against Alzheimer’s disease (AD) and other dementias are all around us.
With new treatments coming to market, such as Leqembi (lecanemab), and a pipeline of 140+ agents in development, providers have increasingly powerful weapons to use against AD — adding to expanding data on the impact of lifestyle interventions.
However, time is of the essence for a paradigm shift in brain health to foster earlier detection and intervention. How can providers — especially those on the front lines in primary care — best adapt to this changing landscape and enhance care for older adults?
Join Alvaro Pascual-Leone, M.D., Ph.D. —chief medical officer and co-founder of Linus Health; professor of neurology at Harvard Medical School; and medical director of the Deanna and Sidney Wolk Center for Memory Health at Hebrew SeniorLife — and John Showalter, M.D. — chief product officer at Linus Health and a dual board-certified primary care physician — as they share insights into the changing landscape of cognitive care, the criticality of early detection, and the role modern cognitive assessment tools can play in streamlining testing and triage.